Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study

Monica Lencioni, Alfredo Falcone, Giacomo Allegrini, Elisabetta Pfanner, Gianluca Masi, Isa Brunetti, Roberta Di Marsico, Eloise Fontana, Cinzia Orlandini, Corrado Gallo Stampino, Carlo Bartolozzi, Pier Franco Conte

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
Issue number3
Publication statusPublished - 2000


  • Doxifluridine
  • Hepatocellular carcinoma
  • Oral chemotherapy
  • Phase II study

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study'. Together they form a unique fingerprint.

Cite this